Kenneth L. Londoner Buys 22,766 Shares of BioSig Technologies, Inc. (NASDAQ:BSGM) Stock

BioSig Technologies, Inc. (NASDAQ:BSGMGet Rating) CEO Kenneth L. Londoner purchased 22,766 shares of the stock in a transaction that occurred on Thursday, September 8th. The shares were purchased at an average cost of $0.84 per share, for a total transaction of $19,123.44. Following the completion of the acquisition, the chief executive officer now directly owns 1,867,120 shares of the company’s stock, valued at approximately $1,568,380.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

BioSig Technologies Trading Up 1.5 %

Shares of BioSig Technologies stock opened at $0.89 on Tuesday. The firm has a 50-day simple moving average of $0.80 and a two-hundred day simple moving average of $0.94. BioSig Technologies, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $4.10.

BioSig Technologies (NASDAQ:BSGMGet Rating) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. BioSig Technologies had a negative return on equity of 253.64% and a negative net margin of 22,438.64%. On average, equities research analysts forecast that BioSig Technologies, Inc. will post -0.64 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BSGM. Warberg Asset Management LLC purchased a new stake in BioSig Technologies in the 2nd quarter worth $43,000. Advisor Group Holdings Inc. grew its position in shares of BioSig Technologies by 394.9% in the first quarter. Advisor Group Holdings Inc. now owns 85,859 shares of the company’s stock valued at $99,000 after purchasing an additional 68,509 shares during the period. Commonwealth Equity Services LLC grew its position in shares of BioSig Technologies by 24.2% in the first quarter. Commonwealth Equity Services LLC now owns 125,705 shares of the company’s stock valued at $144,000 after purchasing an additional 24,500 shares during the period. Finally, Cambridge Investment Research Advisors Inc. increased its stake in shares of BioSig Technologies by 6.7% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 345,807 shares of the company’s stock worth $228,000 after purchasing an additional 21,618 shares in the last quarter. 9.46% of the stock is owned by institutional investors and hedge funds.

About BioSig Technologies

(Get Rating)

BioSig Technologies, Inc, together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time.

Recommended Stories

Insider Buying and Selling by Quarter for BioSig Technologies (NASDAQ:BSGM)

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with's FREE daily email newsletter.